

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **VOLUNTARY ANNOUNCEMENT**

### **ASC40 (TVB-2640) PHASE II NASH TRIAL COMPLETED PATIENT ENROLLMENT IN CHINA**

Reference is made to the announcement of Ascletis Pharma Inc. (the “**Company**”) dated June 17, 2020 (the “**Announcement**”) in relation to the positive results on the non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) from its global Phase II clinical program. Unless otherwise defined, capitalized terms used in this announcement shall bear the same meanings as defined in the Announcement.

The board of directors (the “**Board**”) of the Company is pleased to announce that the patient enrollment in the ASC40 (TVB-2640) Phase II NASH trial in China has been completed. The trial in China with 30 patients enrolled is part of the global Phase II clinical program.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately commercialize ASC40 (TVB-2640) successfully.

By order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People’s Republic of China  
November 19, 2020

*As at the date of this announcement, the Board of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*